Biological regulation of bone quality

Current Osteoporosis Reports

Volumn 12, Issue 3, 2014, Pages 366-375

  Alliston, Tamara ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Bioengineering and Therapeutic Sciences ^*  (United States)

Author keywords

Bone quality; Collagen; Crosslinking; Elastic modulus; Extracellular matrix; Fragility; Mineralization; Nanoindentation; Osteocyte; Osteocyte osteolysis; Perilacunar remodeling; Signaling pathway; TGF Bone remodeling; Transcription factor

Indexed keywords

COLLAGEN; OSTEOCALCIN; OSTEOPONTIN; SCLEROPROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE FRAGILITY; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE QUALITY; BONE REMODELING; BONE STRUCTURE; COLLAGEN METABOLISM; DRUG TARGETING; EXTRACELLULAR MATRIX; HARDNESS; HUMAN; METABOLIC REGULATION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; YOUNG MODULUS; BONE; BONE DENSITY; BONE MATRIX; HOMEOSTASIS; METABOLISM;

BONE AND BONES; BONE DENSITY; BONE MATRIX; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; COLLAGEN; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; SIGNAL TRANSDUCTION;

EID: 84906327430     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0213-4     Document Type: Article

References (98)

1. Hernandez CJ, Keaveny TM. A biomechanical perspective on bone quality. Bone. 2006;39:1173-81. (Pubitemid 44827914)
2. Currey JD. The design of mineralised hard tissues for theirmechanical functions. J Exp Biol. 1999;202:3285-94. (Pubitemid 30018434)
3. Chang JL, Brauer DS, Johnson J, Chen CG, Akil O, Balooch G, et al. Tissue-specific calibration of extracellular matrix material properties by transforming growth factor-beta and Runx2 in bone is required for hearing. EMBO Rep. 2010;11:765-71.
4. Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009;44:648-55.
5. Tommasini SM, Nasser P, Jepsen KJ. Sexual dimorphism affects tibia size and shape but not tissue-level mechanical properties. Bone. 2007;40:498-505. (Pubitemid 46054550)
6. Bouxsein ML, Karasik D. Bone geometry and skeletal fragility. Curr Osteoporos Rep. 2006;4:49-56. (Pubitemid 44623936)
7. Currey JD. The mechanical consequences of variation in the mineral content of bone. J Biomech. 1969;2:1-11.
8. Golub EE. Biomineralization and matrix vesicles in biology and pathology. Semin Immunopath. 2011;33:409-17.
9. Murshed M, McKee MD. Molecular determinants of extracellular matrixmineralization in bone and blood vessels. Curr Opin Nephrol Hypertens. 2010;19:359-65.
10. Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res. 1999;14:2015-26. (Pubitemid 30026950)
11. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002;99:9445-9. (Pubitemid 34764633)
12. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000;289:265-70. (Pubitemid 30469899)
13. • Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803-15. This study demonstrates the regulation of ANK by vitamin D and its role in mineralization.
14. Donnelly E, Chen DX, Boskey AL, Baker SP, van der Meulen MCH. Contribution of mineral to bone structural behavior and tissue mechanical properties. Calcif Tiss Intl. 2010;87:450-60.
15. • Busse B, Bale HA, Zimmermann EA, Panganiban B, Barth HD, Carriero A, et al. Vitamin D deficiency induces early signs of aging in human bone, increasing the risk of fracture. ci Transl Med. 2013;5:193ra88. This study demonstrates the effect of vitamin D deficiency on bone quality at multiple length scales.
16. • Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr Osteoporos Rep. 2012;10:141-50. This is an excellent review on the role of bone matrix proteins and collagen crosslinking in bone quality.
17. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontindeficientmice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999;96:8156-60. (Pubitemid 29328424)
18. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;22:286-97. (Pubitemid 46167799)
19. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382:448-52. (Pubitemid 26264860)
20. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res. 1998;13:1101-11. (Pubitemid 28311778)
21. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J. 1996;317(Pt 1):59-64. (Pubitemid 26238329)
22. Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, et al. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci U S A. 2004;101:1811-5. (Pubitemid 38228973)
23. Zappone B, Thurner PJ, Adams J, Fantner GE, Hansma PK. Effect of Ca2+ ions on the adhesion and mechanical properties of adsorbed layers of human osteopontin. Biophys J. 2008;95:2939-50.
24. •• Poundarik AA, Diab T, Sroga GE, Ural A, Boskey AL, Gundberg CM, et al. Dilatational band formation in bone. Proc Natl Acad Sci U S A. 2012;109:19178-83. This study demonstrates the role of osteocalcin and osteopontin in dilatational bands and the importance of these bands in bone toughness.
25. Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, et al. Osteopontin deficiency increases bone fragility but preserves bone mass. Bone. 2010;46:1564-73.
26. Wallace JM, Rajachar RM, Chen X-D, Shi S, Allen MR, Bloomfield SA, et al. The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone. 2006;39:106-16. (Pubitemid 43842025)
27. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310-5. (Pubitemid 44646294)
28. • Karunaratne A, Esapa CR, Hiller J, Boyde A, Head R, Bassett JH, et al. Significant deterioration in nanomechanical quality occurs through incomplete extrafibrillar mineralization in rachitic bone: evidence from in-situ synchrotron X-ray scattering and backscattered electron imaging. J Bone Miner Res. 2012;27:876-90. This study implicates Phex in the regulation of bone quality.
29. Arteaga-Solis E, Sui-Arteaga L, Kim M, Schaffler MB, Jepsen KJ, Pleshko N, et al. Material and mechanical properties of bones deficient for fibrillin-1 or fibrillin-2 microfibrils. Matrix Biol. 2011;30:188-94.
30. Noda M, Yoon K, Prince CW, Butler WT, Rodan GA. Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem. 1988;263:13916-21.
31. Noda M, Rodan GA. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol. 1989;108:713-8. (Pubitemid 19065866)
32. Leboy PS, Beresford JN, Devlin C, Owen ME. Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures. J Cell Physiol. 1991;146:370-8. (Pubitemid 21910061)
33. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R, Li IW, et al. Regulation of osteopontin expression in osteoblasts. Ann N YAcad Sci. 1995;760:223-41.
34. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, et al. TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A. 2005;102:18813-8. (Pubitemid 43049527)
35. Brennan TC, Rizzoli R, Ammann P. Selective modification of bone quality by PTH, pamidronate, or raloxifene. J Bone Miner Res. 2009;24:800-8.
36. Lane NE, Yao W, Kinney JH, Modin G, Balooch M, Wronski TJ. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res. 2003;18:2105-15. (Pubitemid 37463304)
37. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006;21:466-76.
38. • Carriero A, Doube M, Vogt M, Busse B, Zustin J, Levchuk A, et al. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility. Bone. 2014;61:116-24. This study provides highresolution imaging analysis of bone porosity in ostogenesis imprerfecta.
39. • Carriero A, Zimmermann EA, Paluszny A, Tang SY, Bale H, Busse B, et al. How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone. J Bone Miner Res. 2014. This study examines bone quality in osteogenesis imperfecta at multiple length scales.
40. • Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28:73-80. This study shows the ability of Sclerostin inhibition to improve bone quality in a mouse model of osteogenesis imperfecta.
41. Uveges TE, Kozloff KM, Ty JM, Ledgard F, Raggio CL, Gronowicz G, et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res. 2009;24:849-59.
42. Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr. 1988;35:391-426.
43. Kozloff KM, Carden A, Bergwitz C, Forlino A, Uveges TE, Morris MD, et al. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength. J Bone Miner Res. 2004;19:614-22. (Pubitemid 41071222)
44. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195-214.
45. Burr DB. Bonematerial properties andmineralmatrix contributions to fracture risk or age in women and men. J Musculoskel Neur Inter. 2002;2:201-4. (Pubitemid 34223802)
46. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int. 2009;20:887-94.
47. Nyman JS, Roy A, Tyler JH, Acuna RL, Gayle HJ, Wang X. Agerelated factors affecting the postyield energy dissipation of human cortical bone. J Orthop Res. 2007;25:646-55. (Pubitemid 46730517)
48. Burr DB. Why bones bend but don't break. J Musculoskel Neur Inter. 2011;11:270-85.
49. Diab T, Condon KW, Burr DB, Vashishth D. Age-related change in the damagemorphology of human cortical bone and its role in bone fragility. Bone. 2006;38:427-31. (Pubitemid 43255437)
50. Nalla RK, Kruzic JJ, Kinney JH, Ritchie RO. Effect of aging on the toughness of human cortical bone: evaluation by R-curves. Bone. 2004;35:1240-6. (Pubitemid 40260389)
51. Nyman JS, Even JL, Jo C-H, Herbert EG, Murry MR, Cockrell GE, et al. Increasing duration of type 1 diabetes perturbs the strengthstructure relationship and increases brittleness of bone. Bone. 2011;48:733-40.
52. Gourion-Arsiquaud S, Burket JC, Havill LM, DiCarlo E, Doty SB, Mendelsohn R, et al. Spatial variation in osteonal bone properties relative to tissue and animal age. J Bone Miner Res. 2009;24:1271-81.
53. Burket J, Gourion-Arsiquaud S, Havill LM, Baker SP, Boskey AL, van der Meulen MCH. Microstructure and nanomechanical properties in osteons relate to tissue and animal age. J Biomech. 2011;44:277-84.
54. • Tjhia CK, Stover SM, Rao DS, Odvina CV, Fyhrie DP. Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects. Bone. 2012;51:114-22. This study examines the impact of bisphosphonate treatment and the inhibition of osteoclast-mediated bone remodeling on bone quality.
55. • Seitz S, Koehne T, Ries C, De Novo Oliveira A, Barvencik F, Busse B, et al. Impaired bone mineralization accompanied by low vitamin D and secondary hyperparathyroidismin patients with femoral neck fracture. Osteoporosis Intl. 2013;24:641-9. This study examines the role of signaling pathways that regulate bone remodeling in the regulation of bone quality.
56. Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral andmatrix properties and their heterogeneity. Bone. 2010;46:666-72.
57. • Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55:495-500. This article discusses the mechanisms by which altered bone quality may contribute to atypical femoral fractures following bisphosphonate use.
58. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229-38.
59. Belanger LF. Osteocytic osteolysis. Calcif Tissue Res. 1969;4:1-12.
60. Qing H, Bonewald LF. Osteocyte remodeling of the perilacunar and pericanalicular matrix. Int J Oral Sci. 2009;1:59-65.
61. •• Tang SY, Herber RP, Ho S, Alliston T. Maintenance of Bone Fracture Resistance Requires Perilacunar Remodeling by Matrix Metalloproteinase-13. J Bone Min Res. 2012;27:1936-1950. This article demonstrates the requirement of perilacunar remodeling by osteocytes for the maintenance of bone quality.
62. •• Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012;27:1018-29. This article demonstrates the requirement of perilacunar remodeling by osteocytes for the maintenance of mineral homeostasis.
63. Fuller K, Chambers TJ. Localisation of mRNA for collagenase in osteocytic, bone surface, and chondrocytic cells but not osteoclasts. J Cell Sci. 1995;108(Pt 6):2221-30.
64. Inoue K, Mikuni-Takagaki Y, Oikawa K, Itoh T, Inada M, Noguchi T, et al. A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem. 2006;281:33814-24. (Pubitemid 46036758)
65. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, et al. The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci. 2005;118:147-56. (Pubitemid 40277113)
66. Mosig RA, Dowling O, DiFeo A, Ramirez MCM, Parker IC, Abe E, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bonemineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet. 2007;16:1113-23. (Pubitemid 47062731)
67. Teti A, Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone. 2009;44:11-6.
68. Kerschnitzki M, Wagermaier W, Roschger P, Seto J, Shahar R, Duda GN, et al. The organization of the osteocyte network mirrors the extracellular matrix orientation in bone. J Struct Biol. 2011;173:303-11.
69. • Kerschnitzki M, Kollmannsberger P, Burghammer M, Duda GN, Weinkamer R, Wagermaier W, et al. Architecture of the osteocyte network correlates with bone material quality. J Bone Miner Res. 2013;28:1837-45. This article elegantly shows the relationship between the osteocyte canalicular network and the organization of bone ECM.
70. Nyman JS, Lynch CC, Perrien DS, Thiolloy S, O'Quinn EC, Patil CA, et al. Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res. 2011;26:1252-60.
71. Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res. 2006;21:865-75. (Pubitemid 43787993)
72. • Kühnisch J, Seto J, Lange C, Schrof S, Stumpp S, Kobus K, et al. Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. PLoS One. 2014;9:e86115. This article demonstrates the critical role of a signaling intermediate, NF1, in the control of bone quality.
73. • Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595-611. This article reviews the role of glucocorticoids in osteoporosis and osteonecrosis.
74. • Moutsatsou P, Kassi E, Papavassiliou AG. Glucocorticoid receptor signaling in bone cells. Trends Mol Med. 2012;18:348-59. This review dissects the role of glucocorticoids in osteoblasts, osteocytes, and osteoclasts.
75. • Tang SY, Alliston T. Regulation of postnatal bone homeostasis by TGFbeta. Bonekey Rep. 2013;2:255. This review describes the mechanisms by which TGF β maintains the biological and mechanical homeostasis of bone.
76. Alliston T, Piek E, Derynck R. In: Derynck R, Miyazono K, editors. The TGF-β Family. Woodbury: Cold Spring Harbor Press; 2008. p. 667-723.
77. Dallas SL, Alliston T, Bonewald LF. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. San Diego: Academic Press; 2008. p. 1145-66.
78. Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J, et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and SMAD interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A. 2000;97:10549-54.
79. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-betainduced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001;20:2254-72. (Pubitemid 32410595)
80. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, et al. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE. 2009;4:e5275.
81. Edwards JR, Nyman JS, Lwin ST, Moore MM, Esparza J, O'Quinn EC, et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010;25:2419-26.
82. Ammann P, Brennan TC, Mekraldi S, Aubert ML, Rizzoli R. Administration of growth hormone in selectively proteindeprived rats decreases BMD and bone strength. Bone. 2010;46:1574-81.
83. Tseng KF, Bonadio JF, Stewart TA, Baker AR, Goldstein SA. Local expression of human growth hormone in bone results in impaired mechanical integrity in the skeletal tissue of transgenic mice. J Orthop Res. 1996;14:598-604. (Pubitemid 26278097)
84. Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res. 2011;26:1698-709.
85. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem. 2004;279:41998-2007. (Pubitemid 39313651)
86. • McGee-Lawrence ME, Bradley EW, Dudakovic A, Carlson SW, Ryan ZC, Kumar R, et al. Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone. 2013;52:296-307. This article describes the role of a histone deacetylase in the control of bone ECM quality.
87. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry Syndrome. Cell. 2004;117:387-98. (Pubitemid 38534544)
88. • Makowski AJ, Uppuganti S, Wadeer SA. The loss of activating transcription factor 4 (ATF4) reduces bone toughness and fracture toughness. Bone. 2014;62:1-9. This article describes the role of a transcription factor, ATF4, in control of bone quality.
89. Selvamurugan N, Kwok S, Alliston T, Reiss M, Partridge NC. Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the SMAD and MAPK signaling pathways and their components, SMAD2 and Runx2. J Biol Chem. 2004;279:19327-34. (Pubitemid 38623364)
90. Jepsen KJ, Courtland H-W, Nadeau JH. Genetically determined phenotype covariation networks control bone strength. J Bone Miner Res. 2010;25:1581-93.
91. Havill LM, Allen MR, Bredbenner TL, Burr DB, Nicolella DP, Turner CH, et al. Heritability of lumbar trabecular bone mechanical properties in baboons. Bone. 2010;46:835-40.
92. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9:108-22.
93. • Mullen CA, Haugh MG, Schaffler MB, Majeska RJ, McNamara LM. Osteocyte differentiation is regulated by extracellular matrix stiffness and intercellular separation. J Mech Behav Biomed Mater. 2013;28:183-94. This article demonstrates the importance of cellular tension in osteocyte differentiation.
94. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell. 2006;126:677-89. (Pubitemid 44233625)
95. • Choi JS, Harley BA. The combined influence of substrate elasticity and ligand density on the viability and biophysical properties of hematopoietic stem and progenitor cells. Biomaterials. 2012;33:4460-8. This article demonstrates the importance of cellular tension in HSC differentiation.
96. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res A. 2007;83:136-44. (Pubitemid 47435658)
97. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int. 2002;71:145-54. (Pubitemid 36935480)
98. • Kacena MA, Gundberg CM, Kacena WJ, Landis WJ, Boskey AL, Bouxsein ML, et al. The effects of GATA-1 and NF-E2 deficiency on bone biomechanical, biochemical, and mineral properties. J Cell Physiol. 2013;228:1594-600. This article describes the role of megakaryocyte transcription factors in bone quality.